CRISPR technology has taken the drug discovery space by storm in recent years, but a number of organizations are fighting over who owns what piece of the IP covering its use. (Also see "Editas Competitor CRISPR Therapeutics Hails European Patent Decision" - Scrip, 29 March, 2017.)
Merck KGAA, which has been working with genome editing for many years, claims it has come up with a...






